Article(electronic)#1
Inside CKD: Projecting the Economic Burden of Chronic Kidney Disease (CKD) with Patient-Level Microsimulation Modelling
In: THELANCETPUBLICHEALTH-D-23-01502
Search results
Filter
2 results
Sort by:
Checking availability at your location
This article is also available at your library: |
electronic
print
SSRN
Open Access#22018
Infectious Disease Transmission in Solid Organ Transplantation: Donor Evaluation, Recipient Risk, and Outcomes of Transmission
White, Sarah L; Rawlinson, William; Boan, Peter; Sheppeard, Vicky; Wong, Germaine; Waller, Karen; Opdam, Helen; Kaldor, John
White, Sarah L; Rawlinson, William; Boan, Peter; Sheppeard, Vicky; Wong, Germaine; Waller, Karen; Opdam, Helen; Kaldor, John; Fink, Michael; Verran, Deborah; Webster, Angela; Wyburn, Kate; Grayson, Lindsay; Glanville, Allan; Cross, Nick; Irish, Ashley; Coates, Toby; Griffin, Anthony; Snell, Greg; Alexander, Stephen I; Campbell, Scott; Chadban, Steven; Macdonald, Peter; Manley, Paul; Mehakovic, Eva; Ramachandran, Vidya; Mitchell, Alicia; Ison, Michael
In 2016, the Transplantation Society of Australia and New Zealand, with the support of the Australian Government Organ and Tissue authority, commissioned a literature review on the topic of infectious disease transmission from deceased donors to recipients of solid organ transplants. The purpose of this review was to synthesize evidence on transmission risks, diagnostic test characteristics, and recipient management to inform best-practice clinical guidelines. The final review, presented as a special supplement in Transplantation Direct, collates case reports of transmission events and other peer-reviewed literature, and summarizes current (as of June 2017) international guidelines on donor screening and recipient management. Of particular interest at the time of writing was how to maximize utilization of donors at increased risk for transmission of human immunodeficiency virus, hepatitis C virus, and hepatitis B virus, given the recent developments, including the availability of direct-acting antivirals for hepatitis C virus and improvements in donor screening technologies. The review also covers emerging risks associated with recent epidemics (eg, Zika virus) and the risk of transmission of nonendemic pathogens related to donor travel history or country of origin. Lastly, the implications for recipient consent of expanded utilization of donors at increased risk of blood-borne viral disease transmission are considered.
BASE